Bruce Myers, CFO of Pharmacopeia, will step down ”to pursue other opportunities” in May, following the company’s annual stockholders’ meeting. The Princeton, NJ-based parent company of Accelrys recently ended a dispute between key stockholders and company officials over the proposed acquisition of Eos Biotechnology, which stockholders ultimately voted against. It was not clear what role this played in Myers’ departure.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.